Ordesekimab

DB16649InvestigationalProtein Based Therapies

Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).

Mechanism: Pharmacologically active on Interleukin-15
Curator reviewed
Also known as: Human IgG1 anti-IL-15 monoclonal antibody · Humax IL15 · Humax-IL 15
Code names: AMG-714 · PRV-015

Resolves to

Compound

UNIIEJ48MR05C3CAS2394931-19-0

Targets

P40933IL15

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ordesekimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account